Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04992143

TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC

BCLC Stage C Hepatocellular Carcinoma Clinical Trial

Official title:
The Efficacy and Safety of TACE Combined With Tilelizumab and Sorafenib in Treating BCLC Stage C HCC Patients: a Single-center, Single-arm, Prospective Clinical Study

Clinical Trial Summary

According to the BCLC staging system treatment recommendation, systemic treatment is recommended for patients in BCLC stage C, and TACE and systemic treatment are recommended for patients in this stage. Studies have shown that TACE combined with sorafenib therapy has shown effectiveness in the treatment of advanced liver cancer, and PD-1 inhibitors have also shown effectiveness in the treatment of advanced liver cancer. Therefore, in order to improve the survival benefit of BCLC stage C liver cancer patients, this clinical study was designed to evaluate the effectiveness and safety of TACE combined with sorafenib and tislelizumab in the treatment of BCLC stage C liver cancer patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04992143
Study type Interventional
Source First Affiliated Hospital of Zhejiang University
Contact Jun-hui Sun, MD,PH.D
Phone +86-0571-87236815
Email 1307005@zju.edu.cn
Status Recruiting
Phase Phase 2
Start date August 20, 2021
Completion date December 30, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT01900002 - Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Phase 2
Terminated NCT04777708 - BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer Early Phase 1
Recruiting NCT04204577 - The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer Phase 2
Recruiting NCT04828486 - Futibatinib and Pembrolizumab for Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer Phase 2
Recruiting NCT04736121 - Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients N/A
Not yet recruiting NCT05810402 - Liver Cancer and Immunotherapy in the Liquid Biopsy Era N/A
Recruiting NCT06172205 - Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC Phase 3
Recruiting NCT05199285 - A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab Phase 2
Completed NCT02940496 - Pembrolizumab With or Without Elbasvir/Grazoprevir and Ribavirin in Treating Patients With Advanced Refractory Liver Cancer Phase 2
Withdrawn NCT05327738 - Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma Phase 2
Recruiting NCT04605731 - Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer Phase 1
Recruiting NCT05250895 - BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients With Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy Early Phase 1
Terminated NCT04442581 - Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer Phase 2